BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 10720047)

  • 1. Prognostic value of [18F]fluorodeoxyglucose positron emission tomographic scanning in patients with thyroid cancer.
    Wang W; Larson SM; Fazzari M; Tickoo SK; Kolbert K; Sgouros G; Yeung H; Macapinlac H; Rosai J; Robbins RJ
    J Clin Endocrinol Metab; 2000 Mar; 85(3):1107-13. PubMed ID: 10720047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography scanning.
    Robbins RJ; Wan Q; Grewal RK; Reibke R; Gonen M; Strauss HW; Tuttle RM; Drucker W; Larson SM
    J Clin Endocrinol Metab; 2006 Feb; 91(2):498-505. PubMed ID: 16303836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resistance of [18f]-fluorodeoxyglucose-avid metastatic thyroid cancer lesions to treatment with high-dose radioactive iodine.
    Wang W; Larson SM; Tuttle RM; Kalaigian H; Kolbert K; Sonenberg M; Robbins RJ
    Thyroid; 2001 Dec; 11(12):1169-75. PubMed ID: 12186505
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic (131)I whole body scans and elevated serum thyroglobulin levels.
    Wang W; Macapinlac H; Larson SM; Yeh SD; Akhurst T; Finn RD; Rosai J; Robbins RJ
    J Clin Endocrinol Metab; 1999 Jul; 84(7):2291-302. PubMed ID: 10404792
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of F-18-fluorodeoxyglucose positron emission tomography in the postoperative evaluation of differentiated thyroid cancer.
    Alzahrani AS; Abouzied ME; Salam SA; Mohamed G; Rifai A; Al Sugair A; Amin T
    Eur J Endocrinol; 2008 May; 158(5):683-9. PubMed ID: 18426827
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complementary role of 18F-fluorodeoxyglucose positron emission tomography and 131I scan in the follow-up of post-therapy differentiated thyroid cancer.
    Hsu CH; Liu RS; Wu CH; Chen SM; Shih LS
    J Formos Med Assoc; 2002 Jul; 101(7):459-67. PubMed ID: 12353337
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Do histological, immunohistochemical, and metabolic (radioiodine and fluorodeoxyglucose uptakes) patterns of metastatic thyroid cancer correlate with patient outcome?
    Deandreis D; Al Ghuzlan A; Leboulleux S; Lacroix L; Garsi JP; Talbot M; Lumbroso J; Baudin E; Caillou B; Bidart JM; Schlumberger M
    Endocr Relat Cancer; 2011 Feb; 18(1):159-69. PubMed ID: 21118976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Value of FDG PET in papillary thyroid carcinoma with negative 131I whole-body scan.
    Chung JK; So Y; Lee JS; Choi CW; Lim SM; Lee DS; Hong SW; Youn YK; Lee MC; Cho BY
    J Nucl Med; 1999 Jun; 40(6):986-92. PubMed ID: 10452315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of FDG PET on patients with differentiated thyroid cancer who present with elevated thyroglobulin and negative 131I scan.
    Schlüter B; Bohuslavizki KH; Beyer W; Plotkin M; Buchert R; Clausen M
    J Nucl Med; 2001 Jan; 42(1):71-6. PubMed ID: 11197983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review. 18F-FDG PET in the diagnosis and follow-up of thyroid malignancy.
    Al-Nahhas A; Khan S; Gogbashian A; Banti E; Rampin L; Rubello D
    In Vivo; 2008; 22(1):109-14. PubMed ID: 18396792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The intensity of 18FDG uptake does not predict tumor growth in patients with metastatic differentiated thyroid cancer.
    Terroir M; Borget I; Bidault F; Ricard M; Deschamps F; Hartl D; Tselikas L; Dercle L; Lumbroso J; Baudin E; Berdelou A; Deandreis D; Schlumberger M; Leboulleux S
    Eur J Nucl Med Mol Imaging; 2017 Apr; 44(4):638-646. PubMed ID: 27796544
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FDG PET of recurrent or metastatic 131I-negative papillary thyroid carcinoma.
    Alnafisi NS; Driedger AA; Coates G; Moote DJ; Raphael SJ
    J Nucl Med; 2000 Jun; 41(6):1010-5. PubMed ID: 10855626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluorodeoxyglucose PET/CT in patients with differentiated thyroid cancer and elevated thyroglobulin after total thyroidectomy and (131)I ablation.
    Salvatore B; Paone G; Klain M; Storto G; Nicolai E; D'Amico D; Della Morte AM; Pace L; Salvatore M
    Q J Nucl Med Mol Imaging; 2008 Mar; 52(1):2-8. PubMed ID: 17538522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of 11C-methionine PET and 18F-fluorodeoxyglucose PET in differentiated thyroid cancer.
    Phan HT; Jager PL; Plukker JT; Wolffenbuttel BH; Dierckx RA; Links TP
    Nucl Med Commun; 2008 Aug; 29(8):711-6. PubMed ID: 18753824
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histopathologic characterization of radioactive iodine-refractory fluorodeoxyglucose-positron emission tomography-positive thyroid carcinoma.
    Rivera M; Ghossein RA; Schoder H; Gomez D; Larson SM; Tuttle RM
    Cancer; 2008 Jul; 113(1):48-56. PubMed ID: 18484584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic factors affecting disease-specific survival in patients with recurrent and/or metastatic differentiated thyroid carcinoma detected by positron emission tomography/computed tomography.
    Akkas BE; Demirel BB; Vural GU
    Thyroid; 2014 Feb; 24(2):287-95. PubMed ID: 23750862
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of 18F-fluorodeoxyglucose positron emission tomography in differentiated thyroid cancer before surgery.
    Pak K; Kim SJ; Kim IJ; Kim BH; Kim SS; Jeon YK
    Endocr Relat Cancer; 2013 Aug; 20(4):R203-13. PubMed ID: 23722225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of bone metastases in thyroid cancer patients: bone scintigraphy or 18F-FDG PET?
    Phan HT; Jager PL; Plukker JT; Wolffenbuttel BH; Dierckx RA; Links TP
    Nucl Med Commun; 2007 Aug; 28(8):597-602. PubMed ID: 17625381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer.
    Feine U; Lietzenmayer R; Hanke JP; Held J; Wöhrle H; Müller-Schauenburg W
    J Nucl Med; 1996 Sep; 37(9):1468-72. PubMed ID: 8790195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distant metastatic lesions in patients with differentiated thyroid carcinoma. Clinical implications of radioiodine and FDG uptake.
    Hong CM; Ahn BC; Jeong SY; Lee SW; Lee J
    Nuklearmedizin; 2013; 52(4):121-9. PubMed ID: 23928981
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.